

REMARKS

The specification has been amended to clarify the identity of the sequences and in response to the Notice to Comply with the Sequence Rules.

The brief description of Figure 4 has been amended to include sequence identifiers for the sequences of VMP1, spot ID 22793, spot ID 26883, and the consensus sequence of these sequences. Support for this amendment is found throughout the specification, and in particular, in Figure 4.

To address the issue raised in the Notice to Comply, the brief description of Figure 5 has been amended to include sequence identifiers for the sequences depicted in Figure 5. Support for this amendment is found throughout the specification, and in particular, in Figure 5, which depicts alignments of the sequences of VMP1 to spot ID 22793, VMP1 to spot ID 27450, and VMP1 to spot ID 26883, and page 12, lines 6-10 of the application as filed.

The paragraph beginning on page 88, line 7, has been amended to identify the listed amino acid sequences as fragments of SEQ ID NO: 512. Support for this amendment is found throughout the specification, and in particular, in the originally filed sequence listing.

Finally, Applicant has amended the paragraph starting on page 77, line 20, to correct mislabeling of a sequence as having the same sequence identifier as a nonidentical sequence, an error which was highlighted in the Notice to Comply. Support for this amendment is found throughout the specification, and in particular, in the originally filed sequence listing.

Applicant submits that no new matter has been added with these amendments and requests entry of these amendments.

If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.


In the event the U.S. Patent and Trademark Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. **03-1952** referencing docket no. **223002105200** However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

In addition, please direct all further communications in this application to:

Lisa Alexander
Novartis Vaccines and Diagnostics, Inc., Intellectual Property – R440
P.O. Box 8097
Emeryville, CA 94662-8097
Tel: (510) 923-3004
Fax: (510) 655-3542

Dated: November 6, 2008

Respectfully submitted,

By 

Patricia Tsao

Registration No.: 50,713
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, California 94105-2482
(415) 268-6642